Voyager Therapeutics (NASDAQ:VYGR) Stock Price Up 1.4%

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) shot up 1.4% on Thursday . The stock traded as high as $7.88 and last traded at $7.85. 140,559 shares traded hands during trading, a decline of 85% from the average session volume of 925,631 shares. The stock had previously closed at $7.74.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on VYGR. Citigroup began coverage on Voyager Therapeutics in a research report on Thursday, March 7th. They set a “buy” rating and a $16.00 price objective for the company. Wells Fargo & Company upgraded Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $9.00 to $14.00 in a research report on Tuesday, January 2nd. StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th. Guggenheim began coverage on Voyager Therapeutics in a research report on Tuesday, March 26th. They set a “buy” rating and a $22.00 price objective for the company. Finally, HC Wainwright initiated coverage on Voyager Therapeutics in a research report on Tuesday, March 19th. They set a “buy” rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

Voyager Therapeutics Stock Performance

The business has a fifty day simple moving average of $8.79 and a 200-day simple moving average of $7.95. The firm has a market cap of $410.51 million, a price-to-earnings ratio of 2.52 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of ($0.59) by $1.84. The company had revenue of $90.06 million during the quarter, compared to analysts’ expectations of $4.95 million. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. On average, equities analysts anticipate that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC increased its stake in shares of Voyager Therapeutics by 1.4% in the fourth quarter. Armistice Capital LLC now owns 4,236,000 shares of the company’s stock valued at $35,752,000 after buying an additional 58,000 shares during the period. Vanguard Group Inc. increased its stake in shares of Voyager Therapeutics by 1.9% in the fourth quarter. Vanguard Group Inc. now owns 2,529,668 shares of the company’s stock valued at $21,350,000 after buying an additional 47,711 shares during the period. BlackRock Inc. increased its stake in shares of Voyager Therapeutics by 200.7% in the second quarter. BlackRock Inc. now owns 2,477,400 shares of the company’s stock valued at $28,366,000 after buying an additional 1,653,613 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Voyager Therapeutics by 19.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 932,231 shares of the company’s stock valued at $7,869,000 after buying an additional 153,291 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Voyager Therapeutics by 13.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 901,465 shares of the company’s stock valued at $6,951,000 after buying an additional 104,144 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.